ImmunityBio: Disconnect Between Clinical Progress And Stock Performance
Source: SeekingAlpha
2026-02-25 07:19:07 ET
Overview
Stock of ImmunityBio ( IBRX ), despite my past reservations, has tripled since my last look in July 2025....
Read the full article on Seeking Alpha
For further details see:
ImmunityBio: Disconnect Between Clinical Progress And Stock Performance
ImmunityBio Inc.
NASDAQ: IBRX
IBRX Trading
-5.32% G/L:
$8.087 Last:
10,815,557 Volume:
$8.52 Open:
IBRX Latest News
March 13, 2026 07:30:00 am
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
March 09, 2026 07:30:00 am
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
March 05, 2026 10:20:00 am
Forget ImmunityBio: This Big?Cap Pharma Is the Safer Play on Next?Gen Cancer Therapies
February 27, 2026 07:30:00 am
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
IBRX Stock Data
$6,497,322,803
300,611,373
0.32%
122
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
